APO Research
Talk to an analyst

APO RESEARCH · REPORT

Integrin Alpha 4

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Integrin Alpha 4 Market Outlook and Growth Opportunities 2026

26 December 2025195 pages

Choose your research edition.

Industry ResearchIntegrin Alpha 4 Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Integrin Alpha 4 Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Integrin Alpha 4 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Integrin Alpha 4 Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Integrin Alpha 4 Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Integrin Alpha 4 market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Integrin Alpha 4 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Integrin Alpha 4 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Integrin Alpha 4 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Integrin Alpha 4 market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Integrin Alpha 4 market include Takeda Pharmaceutical Co Ltd, Viriom Inc, Protagonist Therapeutics Inc, Morphic Therapeutic Inc, Immunwork Inc, EA Pharma Co Ltd, Daiichi Sankyo Co Ltd, BioMAS Ltd and Biogen Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Integrin Alpha 4 market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Integrin Alpha 4 and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Integrin Alpha 4 sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Integrin Alpha 4 market size, projected growth trends, production technologies, key applications, and end-use industries.

Integrin Alpha 4 Segment by Company

Takeda Pharmaceutical Co Ltd

Viriom Inc

Protagonist Therapeutics Inc

Morphic Therapeutic Inc

Immunwork Inc

EA Pharma Co Ltd

Daiichi Sankyo Co Ltd

BioMAS Ltd

Biogen Inc

Antisense Therapeutics Ltd

Amgen Inc

Integrin Alpha 4 Segment by Type

ATL-1102

Carotegrast

ET-3764

TE-5232

Others

Integrin Alpha 4 Segment by Application

Acute Ischemic Stroke

Melanoma

Celiac Disease

Multiple Sclerosis

Epilepsy

Other

Integrin Alpha 4 Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Integrin Alpha 4 status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Integrin Alpha 4 market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Integrin Alpha 4 significant trends, drivers, influence factors in global and regions.

6. To analyze Integrin Alpha 4 competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Integrin Alpha 4 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Integrin Alpha 4 and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Integrin Alpha 4.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Integrin Alpha 4 market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Integrin Alpha 4 industry.

Chapter 3: Detailed analysis of Integrin Alpha 4 manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Integrin Alpha 4 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Integrin Alpha 4 in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Integrin Alpha 4 Industry Trends Table 2. Integrin Alpha 4 Industry Drivers Table 3. Integrin Alpha 4 Industry Opportunities and Challenges Table 4. Integrin Alpha 4 Industry Restraints Table 5. Global Integrin Alpha 4 Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Integrin Alpha 4 Revenue Share by Company (2021-2026) Table 7. Global Integrin Alpha 4 Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Integrin Alpha 4 Sales Volume Share by Company (2021-2026) Table 9. Global Integrin Alpha 4 Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Integrin Alpha 4 Company Ranking, (2024-2026) & (USD Million) Table 11. Global Integrin Alpha 4 Key Company Manufacturing Base & Headquarters Table 12. Global Integrin Alpha 4 Company, Product Type & Application Table 13. Global Integrin Alpha 4 Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Integrin Alpha 4 by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of ATL-1102 Table 18. Significant Companies of Carotegrast Table 19. Significant Companies of ET-3764 Table 20. Significant Companies of TE-5232 Table 21. Significant Companies of Others Table 22. Global Integrin Alpha 4 Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 23. Global Integrin Alpha 4 Sales Volume by Type (2021-2026) & (W Units) Table 24. Global Integrin Alpha 4 Sales Volume by Type (2027-2032) & (W Units) Table 25. Global Integrin Alpha 4 Sales Volume Share by Type (2021-2026) Table 26. Global Integrin Alpha 4 Sales Volume Share by Type (2027-2032) Table 27. Global Integrin Alpha 4 Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Integrin Alpha 4 Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Integrin Alpha 4 Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Integrin Alpha 4 Sales Value Share by Type (2021-2026) Table 31. Global Integrin Alpha 4 Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Acute Ischemic Stroke Table 33. Significant Companies of Melanoma Table 34. Significant Companies of Celiac Disease Table 35. Significant Companies of Multiple Sclerosis Table 36. Significant Companies of Epilepsy Table 37. Significant Companies of Other Table 38. Global Integrin Alpha 4 Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 39. Global Integrin Alpha 4 Sales Volume by Application (2021-2026) & (W Units) Table 40. Global Integrin Alpha 4 Sales Volume by Application (2027-2032) & (W Units) Table 41. Global Integrin Alpha 4 Sales Volume Share by Application (2021-2026) Table 42. Global Integrin Alpha 4 Sales Volume Share by Application (2027-2032) Table 43. Global Integrin Alpha 4 Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 44. Global Integrin Alpha 4 Sales Value by Application (2021-2026) & (US$ Million) Table 45. Global Integrin Alpha 4 Sales Value by Application (2027-2032) & (US$ Million) Table 46. Global Integrin Alpha 4 Sales Value Share by Application (2021-2026) Table 47. Global Integrin Alpha 4 Sales Value Share by Application (2027-2032) Table 48. Global Integrin Alpha 4 Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 49. Global Integrin Alpha 4 Sales by Region (2021-2026) & (W Units) Table 50. Global Integrin Alpha 4 Sales Market Share by Region (2021-2026) Table 51. Global Integrin Alpha 4 Sales by Region (2027-2032) & (W Units) Table 52. Global Integrin Alpha 4 Sales Market Share by Region (2027-2032) Table 53. Global Integrin Alpha 4 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 54. Global Integrin Alpha 4 Sales Value by Region (2021-2026) & (US$ Million) Table 55. Global Integrin Alpha 4 Sales Value Share by Region (2021-2026) Table 56. Global Integrin Alpha 4 Sales Value by Region (2027-2032) & (US$ Million) Table 57. Global Integrin Alpha 4 Sales Value Share by Region (2027-2032) Table 58. Global Integrin Alpha 4 Market Average Price (US$/Unit) by Region (2021-2026) Table 59. Global Integrin Alpha 4 Market Average Price (US$/Unit) by Region (2027-2032) Table 60. Global Integrin Alpha 4 Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 61. Global Integrin Alpha 4 Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Integrin Alpha 4 Sales by Country (2021-2026) & (W Units) Table 63. Global Integrin Alpha 4 Sales Market Share by Country (2021-2026) Table 64. Global Integrin Alpha 4 Sales by Country (2027-2032) & (W Units) Table 65. Global Integrin Alpha 4 Sales Market Share by Country (2027-2032) Table 66. Global Integrin Alpha 4 Sales Value by Country (2021-2026) & (US$ Million) Table 67. Global Integrin Alpha 4 Sales Value Market Share by Country (2021-2026) Table 68. Global Integrin Alpha 4 Sales Value by Country (2027-2032) & (US$ Million) Table 69. Global Integrin Alpha 4 Sales Value Market Share by Country (2027-2032) Table 70. Takeda Pharmaceutical Co Ltd Company Information Table 71. Takeda Pharmaceutical Co Ltd Business Overview Table 72. Takeda Pharmaceutical Co Ltd Integrin Alpha 4 Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Takeda Pharmaceutical Co Ltd Integrin Alpha 4 Product Portfolio Table 74. Takeda Pharmaceutical Co Ltd Recent Development Table 75. Viriom Inc Company Information Table 76. Viriom Inc Business Overview Table 77. Viriom Inc Integrin Alpha 4 Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Viriom Inc Integrin Alpha 4 Product Portfolio Table 79. Viriom Inc Recent Development Table 80. Protagonist Therapeutics Inc Company Information Table 81. Protagonist Therapeutics Inc Business Overview Table 82. Protagonist Therapeutics Inc Integrin Alpha 4 Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Protagonist Therapeutics Inc Integrin Alpha 4 Product Portfolio Table 84. Protagonist Therapeutics Inc Recent Development Table 85. Morphic Therapeutic Inc Company Information Table 86. Morphic Therapeutic Inc Business Overview Table 87. Morphic Therapeutic Inc Integrin Alpha 4 Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Morphic Therapeutic Inc Integrin Alpha 4 Product Portfolio Table 89. Morphic Therapeutic Inc Recent Development Table 90. Immunwork Inc Company Information Table 91. Immunwork Inc Business Overview Table 92. Immunwork Inc Integrin Alpha 4 Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Immunwork Inc Integrin Alpha 4 Product Portfolio Table 94. Immunwork Inc Recent Development Table 95. EA Pharma Co Ltd Company Information Table 96. EA Pharma Co Ltd Business Overview Table 97. EA Pharma Co Ltd Integrin Alpha 4 Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. EA Pharma Co Ltd Integrin Alpha 4 Product Portfolio Table 99. EA Pharma Co Ltd Recent Development Table 100. Daiichi Sankyo Co Ltd Company Information Table 101. Daiichi Sankyo Co Ltd Business Overview Table 102. Daiichi Sankyo Co Ltd Integrin Alpha 4 Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Daiichi Sankyo Co Ltd Integrin Alpha 4 Product Portfolio Table 104. Daiichi Sankyo Co Ltd Recent Development Table 105. BioMAS Ltd Company Information Table 106. BioMAS Ltd Business Overview Table 107. BioMAS Ltd Integrin Alpha 4 Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. BioMAS Ltd Integrin Alpha 4 Product Portfolio Table 109. BioMAS Ltd Recent Development Table 110. Biogen Inc Company Information Table 111. Biogen Inc Business Overview Table 112. Biogen Inc Integrin Alpha 4 Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Biogen Inc Integrin Alpha 4 Product Portfolio Table 114. Biogen Inc Recent Development Table 115. Antisense Therapeutics Ltd Company Information Table 116. Antisense Therapeutics Ltd Business Overview Table 117. Antisense Therapeutics Ltd Integrin Alpha 4 Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Antisense Therapeutics Ltd Integrin Alpha 4 Product Portfolio Table 119. Antisense Therapeutics Ltd Recent Development Table 120. Amgen Inc Company Information Table 121. Amgen Inc Business Overview Table 122. Amgen Inc Integrin Alpha 4 Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Amgen Inc Integrin Alpha 4 Product Portfolio Table 124. Amgen Inc Recent Development Table 125. Key Raw Materials Table 126. Raw Materials Key Suppliers Table 127. Integrin Alpha 4 Distributors List Table 128. Integrin Alpha 4 Customers List Table 129. Research Programs/Design for This Report Table 130. Authors List of This Report Table 131. Secondary Sources Table 132. Primary Sources List of Figures Figure 1. Integrin Alpha 4 Product Image Figure 2. Global Integrin Alpha 4 Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Integrin Alpha 4 Sales Value (2021-2032) & (US$ Million) Figure 4. Global Integrin Alpha 4 Sales (2021-2032) & (W Units) Figure 5. Global Integrin Alpha 4 Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Integrin Alpha 4 Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. ATL-1102 Image Figure 10. Carotegrast Image Figure 11. ET-3764 Image Figure 12. TE-5232 Image Figure 13. Others Image Figure 14. Global Integrin Alpha 4 Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 15. Global Integrin Alpha 4 Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Integrin Alpha 4 Sales Volume Share by Type (2021-2032) Figure 17. Global Integrin Alpha 4 Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Integrin Alpha 4 Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Integrin Alpha 4 Sales Value Share by Type (2021-2032) Figure 20. Acute Ischemic Stroke Image Figure 21. Melanoma Image Figure 22. Celiac Disease Image Figure 23. Multiple Sclerosis Image Figure 24. Epilepsy Image Figure 25. Other Image Figure 26. Global Integrin Alpha 4 Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 27. Global Integrin Alpha 4 Sales Volume Share 2021 VS 2025 VS 2032 Figure 28. Global Integrin Alpha 4 Sales Volume Share by Application (2021-2032) Figure 29. Global Integrin Alpha 4 Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Integrin Alpha 4 Sales Value Share 2021 VS 2025 VS 2032 Figure 31. Global Integrin Alpha 4 Sales Value Share by Application (2021-2032) Figure 32. Global Integrin Alpha 4 Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 33. Global Integrin Alpha 4 Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 34. Global Integrin Alpha 4 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 35. Global Integrin Alpha 4 Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 36. North America Integrin Alpha 4 Sales Value (2021-2032) & (US$ Million) Figure 37. North America Integrin Alpha 4 Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Europe Integrin Alpha 4 Sales Value (2021-2032) & (US$ Million) Figure 39. Europe Integrin Alpha 4 Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Asia-Pacific Integrin Alpha 4 Sales Value (2021-2032) & (US$ Million) Figure 41. Asia-Pacific Integrin Alpha 4 Sales Value Share by Country (%), 2025 VS 2032 Figure 42. South America Integrin Alpha 4 Sales Value (2021-2032) & (US$ Million) Figure 43. South America Integrin Alpha 4 Sales Value Share by Country (%), 2025 VS 2032 Figure 44. Middle East & Africa Integrin Alpha 4 Sales Value (2021-2032) & (US$ Million) Figure 45. Middle East & Africa Integrin Alpha 4 Sales Value Share by Country (%), 2025 VS 2032 Figure 46. USA Integrin Alpha 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. USA Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. USA Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Canada Integrin Alpha 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Canada Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Canada Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Mexico Integrin Alpha 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Mexico Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Mexico Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Germany Integrin Alpha 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Germany Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Germany Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. France Integrin Alpha 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. France Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. France Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. U.K. Integrin Alpha 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. U.K. Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. U.K. Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Italy Integrin Alpha 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Italy Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Italy Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Spain Integrin Alpha 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Spain Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Spain Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Russia Integrin Alpha 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Russia Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Russia Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Netherlands Integrin Alpha 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Netherlands Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Netherlands Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Nordic Countries Integrin Alpha 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Nordic Countries Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Nordic Countries Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. China Integrin Alpha 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. China Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. China Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Japan Integrin Alpha 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Japan Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Japan Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. South Korea Integrin Alpha 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. South Korea Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. South Korea Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. India Integrin Alpha 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. India Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. India Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Australia Integrin Alpha 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Australia Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Australia Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Southeast Asia Integrin Alpha 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Southeast Asia Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Southeast Asia Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Brazil Integrin Alpha 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Brazil Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Brazil Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Argentina Integrin Alpha 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Argentina Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Argentina Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Chile Integrin Alpha 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Chile Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Chile Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Colombia Integrin Alpha 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Colombia Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Colombia Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Peru Integrin Alpha 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Peru Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Peru Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Integrin Alpha 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Saudi Arabia Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Saudi Arabia Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Israel Integrin Alpha 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Israel Arabia Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Israel Arabia Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. UAE Integrin Alpha 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. UAE Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. UAE Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Turkey Integrin Alpha 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Turkey Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Turkey Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Iran Integrin Alpha 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Iran Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Iran Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Egypt Integrin Alpha 4 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 128. Egypt Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 129. Egypt Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 130. Integrin Alpha 4 Value Chain Figure 131. Manufacturing Cost Structure Figure 132. Integrin Alpha 4 Sales Mode & Process Figure 133. Direct Comparison with Distribution Share Figure 134. Distributors Profiles Figure 135. Years Considered Figure 136. Research Process Figure 137. Key Executives Interviewed

Scope & coverage.

Types
  • ATL-1102
  • Carotegrast
  • ET-3764
  • TE-5232
  • Others
Applications
  • Acute Ischemic Stroke
  • Melanoma
  • Celiac Disease
  • Multiple Sclerosis
  • Epilepsy
  • Other
Companies covered
  • Takeda Pharmaceutical Co Ltd
  • Viriom Inc
  • Protagonist Therapeutics Inc
  • Morphic Therapeutic Inc
  • Immunwork Inc
  • EA Pharma Co Ltd
  • Daiichi Sankyo Co Ltd
  • BioMAS Ltd
  • Biogen Inc
  • Antisense Therapeutics Ltd
  • Amgen Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Integrin Alpha 4 Sales Value (2021-2032)
  4. 1.2.2 Global Integrin Alpha 4 Sales Volume (2021-2032)
  5. 1.2.3 Global Integrin Alpha 4 Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Integrin Alpha 4 Market Dynamics
  1. 2.1 Integrin Alpha 4 Industry Trends
  2. 2.2 Integrin Alpha 4 Industry Drivers
  3. 2.3 Integrin Alpha 4 Industry Opportunities and Challenges
  4. 2.4 Integrin Alpha 4 Industry Restraints
3 Integrin Alpha 4 Market by Company
  1. 3.1 Global Integrin Alpha 4 Company Revenue Ranking in 2025
  2. 3.2 Global Integrin Alpha 4 Revenue by Company (2021-2026)
  3. 3.3 Global Integrin Alpha 4 Sales Volume by Company (2021-2026)
  4. 3.4 Global Integrin Alpha 4 Average Price by Company (2021-2026)
  5. 3.5 Global Integrin Alpha 4 Company Ranking (2024-2026)
  6. 3.6 Global Integrin Alpha 4 Company Manufacturing Base and Headquarters
  7. 3.7 Global Integrin Alpha 4 Company Product Type and Application
  8. 3.8 Global Integrin Alpha 4 Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Integrin Alpha 4 Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Integrin Alpha 4 Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Integrin Alpha 4 Market by Type
  1. 4.1 Integrin Alpha 4 Type Introduction
  2. 4.1.1 ATL-1102
  3. 4.1.2 Carotegrast
  4. 4.1.3 ET-3764
  5. 4.1.4 TE-5232
  6. 4.1.5 Others
  7. 4.2 Global Integrin Alpha 4 Sales Volume by Type
  8. 4.2.1 Global Integrin Alpha 4 Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Integrin Alpha 4 Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Integrin Alpha 4 Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Integrin Alpha 4 Sales Value by Type
  12. 4.3.1 Global Integrin Alpha 4 Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Integrin Alpha 4 Sales Value by Type (2021-2032)
  14. 4.3.3 Global Integrin Alpha 4 Sales Value Share by Type (2021-2032)
5 Integrin Alpha 4 Market by Application
  1. 5.1 Integrin Alpha 4 Application Introduction
  2. 5.1.1 Acute Ischemic Stroke
  3. 5.1.2 Melanoma
  4. 5.1.3 Celiac Disease
  5. 5.1.4 Multiple Sclerosis
  6. 5.1.5 Epilepsy
  7. 5.1.6 Other
  8. 5.2 Global Integrin Alpha 4 Sales Volume by Application
  9. 5.2.1 Global Integrin Alpha 4 Sales Volume by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Integrin Alpha 4 Sales Volume by Application (2021-2032)
  11. 5.2.3 Global Integrin Alpha 4 Sales Volume Share by Application (2021-2032)
  12. 5.3 Global Integrin Alpha 4 Sales Value by Application
  13. 5.3.1 Global Integrin Alpha 4 Sales Value by Application (2021 VS 2025 VS 2032)
  14. 5.3.2 Global Integrin Alpha 4 Sales Value by Application (2021-2032)
  15. 5.3.3 Global Integrin Alpha 4 Sales Value Share by Application (2021-2032)
6 Integrin Alpha 4 Regional Sales and Value Analysis
  1. 6.1 Global Integrin Alpha 4 Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Integrin Alpha 4 Sales by Region (2021-2032)
  3. 6.2.1 Global Integrin Alpha 4 Sales by Region: 2021-2026
  4. 6.2.2 Global Integrin Alpha 4 Sales by Region (2027-2032)
  5. 6.3 Global Integrin Alpha 4 Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Integrin Alpha 4 Sales Value by Region (2021-2032)
  7. 6.4.1 Global Integrin Alpha 4 Sales Value by Region: 2021-2026
  8. 6.4.2 Global Integrin Alpha 4 Sales Value by Region (2027-2032)
  9. 6.5 Global Integrin Alpha 4 Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Integrin Alpha 4 Sales Value (2021-2032)
  12. 6.6.2 North America Integrin Alpha 4 Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Integrin Alpha 4 Sales Value (2021-2032)
  15. 6.7.2 Europe Integrin Alpha 4 Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Integrin Alpha 4 Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Integrin Alpha 4 Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Integrin Alpha 4 Sales Value (2021-2032)
  21. 6.9.2 South America Integrin Alpha 4 Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Integrin Alpha 4 Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Integrin Alpha 4 Sales Value Share by Country, 2025 VS 2032
7 Integrin Alpha 4 Country-level Sales and Value Analysis
  1. 7.1 Global Integrin Alpha 4 Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Integrin Alpha 4 Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Integrin Alpha 4 Sales by Country (2021-2032)
  4. 7.3.1 Global Integrin Alpha 4 Sales by Country (2021-2026)
  5. 7.3.2 Global Integrin Alpha 4 Sales by Country (2027-2032)
  6. 7.4 Global Integrin Alpha 4 Sales Value by Country (2021-2032)
  7. 7.4.1 Global Integrin Alpha 4 Sales Value by Country (2021-2026)
  8. 7.4.2 Global Integrin Alpha 4 Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Integrin Alpha 4 Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Integrin Alpha 4 Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Integrin Alpha 4 Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Integrin Alpha 4 Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Integrin Alpha 4 Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Integrin Alpha 4 Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Integrin Alpha 4 Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Integrin Alpha 4 Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Integrin Alpha 4 Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Integrin Alpha 4 Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Integrin Alpha 4 Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Integrin Alpha 4 Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Integrin Alpha 4 Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Integrin Alpha 4 Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Integrin Alpha 4 Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Integrin Alpha 4 Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Integrin Alpha 4 Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Integrin Alpha 4 Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Integrin Alpha 4 Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Integrin Alpha 4 Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Integrin Alpha 4 Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Integrin Alpha 4 Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Integrin Alpha 4 Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Integrin Alpha 4 Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Integrin Alpha 4 Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Integrin Alpha 4 Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Integrin Alpha 4 Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Integrin Alpha 4 Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Integrin Alpha 4 Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Integrin Alpha 4 Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceutical Co Ltd
  2. 8.1.1 Takeda Pharmaceutical Co Ltd Company Information
  3. 8.1.2 Takeda Pharmaceutical Co Ltd Business Overview
  4. 8.1.3 Takeda Pharmaceutical Co Ltd Integrin Alpha 4 Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceutical Co Ltd Integrin Alpha 4 Product Portfolio
  6. 8.1.5 Takeda Pharmaceutical Co Ltd Recent Developments
  7. 8.2 Viriom Inc
  8. 8.2.1 Viriom Inc Company Information
  9. 8.2.2 Viriom Inc Business Overview
  10. 8.2.3 Viriom Inc Integrin Alpha 4 Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Viriom Inc Integrin Alpha 4 Product Portfolio
  12. 8.2.5 Viriom Inc Recent Developments
  13. 8.3 Protagonist Therapeutics Inc
  14. 8.3.1 Protagonist Therapeutics Inc Company Information
  15. 8.3.2 Protagonist Therapeutics Inc Business Overview
  16. 8.3.3 Protagonist Therapeutics Inc Integrin Alpha 4 Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Protagonist Therapeutics Inc Integrin Alpha 4 Product Portfolio
  18. 8.3.5 Protagonist Therapeutics Inc Recent Developments
  19. 8.4 Morphic Therapeutic Inc
  20. 8.4.1 Morphic Therapeutic Inc Company Information
  21. 8.4.2 Morphic Therapeutic Inc Business Overview
  22. 8.4.3 Morphic Therapeutic Inc Integrin Alpha 4 Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Morphic Therapeutic Inc Integrin Alpha 4 Product Portfolio
  24. 8.4.5 Morphic Therapeutic Inc Recent Developments
  25. 8.5 Immunwork Inc
  26. 8.5.1 Immunwork Inc Company Information
  27. 8.5.2 Immunwork Inc Business Overview
  28. 8.5.3 Immunwork Inc Integrin Alpha 4 Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Immunwork Inc Integrin Alpha 4 Product Portfolio
  30. 8.5.5 Immunwork Inc Recent Developments
  31. 8.6 EA Pharma Co Ltd
  32. 8.6.1 EA Pharma Co Ltd Company Information
  33. 8.6.2 EA Pharma Co Ltd Business Overview
  34. 8.6.3 EA Pharma Co Ltd Integrin Alpha 4 Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 EA Pharma Co Ltd Integrin Alpha 4 Product Portfolio
  36. 8.6.5 EA Pharma Co Ltd Recent Developments
  37. 8.7 Daiichi Sankyo Co Ltd
  38. 8.7.1 Daiichi Sankyo Co Ltd Company Information
  39. 8.7.2 Daiichi Sankyo Co Ltd Business Overview
  40. 8.7.3 Daiichi Sankyo Co Ltd Integrin Alpha 4 Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Daiichi Sankyo Co Ltd Integrin Alpha 4 Product Portfolio
  42. 8.7.5 Daiichi Sankyo Co Ltd Recent Developments
  43. 8.8 BioMAS Ltd
  44. 8.8.1 BioMAS Ltd Company Information
  45. 8.8.2 BioMAS Ltd Business Overview
  46. 8.8.3 BioMAS Ltd Integrin Alpha 4 Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 BioMAS Ltd Integrin Alpha 4 Product Portfolio
  48. 8.8.5 BioMAS Ltd Recent Developments
  49. 8.9 Biogen Inc
  50. 8.9.1 Biogen Inc Company Information
  51. 8.9.2 Biogen Inc Business Overview
  52. 8.9.3 Biogen Inc Integrin Alpha 4 Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Biogen Inc Integrin Alpha 4 Product Portfolio
  54. 8.9.5 Biogen Inc Recent Developments
  55. 8.10 Antisense Therapeutics Ltd
  56. 8.10.1 Antisense Therapeutics Ltd Company Information
  57. 8.10.2 Antisense Therapeutics Ltd Business Overview
  58. 8.10.3 Antisense Therapeutics Ltd Integrin Alpha 4 Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Antisense Therapeutics Ltd Integrin Alpha 4 Product Portfolio
  60. 8.10.5 Antisense Therapeutics Ltd Recent Developments
  61. 8.11 Amgen Inc
  62. 8.11.1 Amgen Inc Company Information
  63. 8.11.2 Amgen Inc Business Overview
  64. 8.11.3 Amgen Inc Integrin Alpha 4 Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Amgen Inc Integrin Alpha 4 Product Portfolio
  66. 8.11.5 Amgen Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Integrin Alpha 4 Value Chain Analysis
  2. 9.1.1 Integrin Alpha 4 Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Integrin Alpha 4 Sales Mode & Process
  6. 9.2 Integrin Alpha 4 Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Integrin Alpha 4 Distributors
  9. 9.2.3 Integrin Alpha 4 Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst